Compositions and methods for immunotherapy
AssigneeNexlmmune, Inc.
InventorsBruce McCreedy, Timothy David Jones, Francis Joseph Carr
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.
Claims26
A pharmaceutical composition comprising:
- polymeric PLGA-PEG particles having a size in the range of about 100 to 200 nm, a surface charge of about 0 to -20 mV, and from about 100 to 1500 protein ligands per particle, the protein ligands optionally coupled through a sulfhydryl-maleimide chemistry;
- a population of anti-CD28 antibody ligands;
- a population of HLA ligands;
- one or more antigenic peptides for presentation to T cells;
- and
- a pharmaceutically acceptable carrier for intravenous, intra-arterial, subcutaneous, intradermal, intralymphatic, or intra-tumoral administration.
(canceled)
(canceled)
(canceled)
An anti-CD28 antibody or portion thereof, comprising a human IGHV4 heavy chain amino acid sequence optionally with from one to fifteen amino acid modifications, wherein at least one complementarity determining region (CDR) is based on a murine antibody amino acid sequence.
19-37. (canceled)
An antigen presenting complex comprising a humanized immunoglobulin heavy chain sequence fused to an HLA amino acid sequence, wherein the complex optionally does not contain an immunoglobulin light chain sequence.
39-46. (canceled)
48-66. (canceled)
Dependencies are inferred from the claim text.